[
  {
    "ts": null,
    "headline": "Danaher Corp. stock underperforms Friday when compared to competitors",
    "summary": "Danaher Corp. stock underperforms Friday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=d8495ef86381c644d1b580f3558e45b6cb63dd32f9c5cd8d47fdf87f153fda3a",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743784500,
      "headline": "Danaher Corp. stock underperforms Friday when compared to competitors",
      "id": 133745223,
      "image": "",
      "related": "DHR",
      "source": "MarketWatch",
      "summary": "Danaher Corp. stock underperforms Friday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=d8495ef86381c644d1b580f3558e45b6cb63dd32f9c5cd8d47fdf87f153fda3a"
    }
  },
  {
    "ts": null,
    "headline": "Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds",
    "summary": "DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.",
    "url": "https://finnhub.io/api/news?id=78dd42efad46d761080dca312eb044a329154c3212b1d64d723a71dd22d23134",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743782220,
      "headline": "Danaher Gains From Strength in the Diagnostics Unit Amid Headwinds",
      "id": 133719530,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "DHR",
      "source": "Yahoo",
      "summary": "DHR is poised to gain from strength in the clinical diagnostics business, the Abcam buyout and shareholder-friendly policies. Softness in Life Sciences and Biotechnology units remains a concern.",
      "url": "https://finnhub.io/api/news?id=78dd42efad46d761080dca312eb044a329154c3212b1d64d723a71dd22d23134"
    }
  },
  {
    "ts": null,
    "headline": "Andvari Associates Q1 2025 Letter",
    "summary": "For Q1 2025, Andvari is up 7.2% net of fees while the SPDR S&P 500 ETF (SPY) is down 4.3%. Click here to read the full letter.",
    "url": "https://finnhub.io/api/news?id=61791deedff4c44e8e2d77783ef2274c21fb02347e8926a885f9e07dc64b7870",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1743758700,
      "headline": "Andvari Associates Q1 2025 Letter",
      "id": 133704549,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/942696884/image_942696884.jpg?io=getty-c-w1536",
      "related": "DHR",
      "source": "SeekingAlpha",
      "summary": "For Q1 2025, Andvari is up 7.2% net of fees while the SPDR S&P 500 ETF (SPY) is down 4.3%. Click here to read the full letter. ",
      "url": "https://finnhub.io/api/news?id=61791deedff4c44e8e2d77783ef2274c21fb02347e8926a885f9e07dc64b7870"
    }
  }
]